Sandra Tourt-Uhlig

2.4k total citations · 1 hit paper
12 papers, 1.3k citations indexed

About

Sandra Tourt-Uhlig is a scholar working on Genetics, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Sandra Tourt-Uhlig has authored 12 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Genetics, 4 papers in Molecular Biology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Sandra Tourt-Uhlig's work include Glioma Diagnosis and Treatment (8 papers), Cancer therapeutics and mechanisms (3 papers) and Brain Metastases and Treatment (3 papers). Sandra Tourt-Uhlig is often cited by papers focused on Glioma Diagnosis and Treatment (8 papers), Cancer therapeutics and mechanisms (3 papers) and Brain Metastases and Treatment (3 papers). Sandra Tourt-Uhlig collaborates with scholars based in United States, United Kingdom and France. Sandra Tourt-Uhlig's co-authors include Henry S. Friedman, James E. Herndon, Roger E. McLendon, David A. Reardon, Allan H. Friedman, Jennifer A. Quinn, Jeremy N. Rich, John H. Sampson, Darell D. Bigner and Sridharan Gururangan and has published in prestigious journals such as Journal of Clinical Oncology, American Heart Journal and Neuro-Oncology.

In The Last Decade

Sandra Tourt-Uhlig

12 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase II Trial of Gefitinib in Recurrent Glioblastoma

2003 558 citations Jeremy N. Rich, David A. Reardon et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Sandra Tourt-Uhlig

Since Specialization

Citations

This map shows the geographic impact of Sandra Tourt-Uhlig's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sandra Tourt-Uhlig with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sandra Tourt-Uhlig more than expected).

Fields of papers citing papers by Sandra Tourt-Uhlig

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sandra Tourt-Uhlig. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sandra Tourt-Uhlig. The network helps show where Sandra Tourt-Uhlig may publish in the future.

Co-authorship network of co-authors of Sandra Tourt-Uhlig

This figure shows the co-authorship network connecting the top 25 collaborators of Sandra Tourt-Uhlig. A scholar is included among the top collaborators of Sandra Tourt-Uhlig based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sandra Tourt-Uhlig. Sandra Tourt-Uhlig is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

#	Work	Indexed citations
1	Levosimendan in patients with left ventricular systolic dysfunction undergoing cardiac surgery on cardiopulmonary bypass: Rationale and study design of the Levosimendan in Patients with Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery Requiring Cardiopulmonary Bypass (LEVO-CTS) trial 2016 ·American Heart Journal ·Rajendra H. Mehta, Sean van Diepen, James P. Meza, Paula M. Bokesch, Jeffrey D. Leimberger, Sandra Tourt-Uhlig, (unknown), (unknown), Rachael Jankowich, Douglas W.P. Hay, Robert W. Harrison, Stephen E. Fremes, Shaun G. Goodman, John M. Luber, Wolfgang Toller, Matthias Heringlake, Kevin J. Anstrom, Jerrold H. Levy, Robert A. Harrington, John H. Alexander	19
2	Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: Study design and conduct 2013 ·American Heart Journal ·Renato D. Lópes, (unknown), Gail E. Hafley, (unknown), Sandra Tourt-Uhlig, Jennifer White, L. Kristin Newby, Michel Komajda, John J.V. McMurray, Robert Bigelow, Philip Home, Kenneth W. Mahaffey	18
3	Results of a reevaluation of cardiovascular outcomes in the RECORD trial 2013 ·American Heart Journal ·Kenneth W. Mahaffey, Gail E. Hafley, (unknown), (unknown), Sandra Tourt-Uhlig, Jennifer A. White, L. Kristin Newby, Michel Komajda, John J.V. McMurray, Robert Bigelow, Philip Home, Renato D. Lópes	129
4	Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors. 2012 ·Journal of Clinical Oncology ·Fatima Rangwala, Johanna C. Bendell, M. Kozloff, (unknown), (unknown), Sandra Tourt-Uhlig, Jennifer Murphy, Kellen L. Meadows, Michael A. Morse, Hope E. Uronis, Shiaowen David Hsu, S. Yousuf Zafar, Herbert I. Hurwitz	3
5	Phase 1 trial of irinotecan plus BCNU in patients with progressive orrecurrent malignant glioma 2004 ·Neuro-Oncology ·Jennifer A. Quinn, David A. Reardon, Allan H. Friedman, Jeremy N. Rich, John H. Sampson, James J. Vredenburgh, Sridharan Gururangan, James M. Provenzale, Amy Walker, (unknown), Darell D. Bigner, Sandra Tourt-Uhlig, James E. Herndon, Mary Lou Affronti, (unknown), Deborah H. Allen, (unknown), (unknown), (unknown), Henry S. Friedman	24
6	Phase II Trial of Temozolomide in Patients With Progressive Low-Grade Glioma 2003 ·Journal of Clinical Oncology ·Jennifer A. Quinn, David A. Reardon, Allan H. Friedman, Jeremy N. Rich, John H. Sampson, James M. Provenzale, Roger E. McLendon, Sridharan Gururangan, Darell D. Bigner, James E. Herndon, Nicholas G. Avgeropoulos, Jonathan L. Finlay, Sandra Tourt-Uhlig, Mary Lou Affronti, (unknown), (unknown), Sara Zaknoen, Henry S. Friedman	182
7	Phase II Trial of Gefitinib in Recurrent Glioblastoma breakdown → 2003 ·Journal of Clinical Oncology ·Jeremy N. Rich, David A. Reardon, (unknown), Jeannette M. Dowell, Jennifer A. Quinn, Kara Penne, Carol J. Wikstrand, (unknown), Janet Dancey, Roger E. McLendon, James C. Kao, Timothy T. Stenzel, Binish Rasheed, Sandra Tourt-Uhlig, James E. Herndon, James J. Vredenburgh, John H. Sampson, Allan H. Friedman, Darell D. Bigner, Henry S. Friedman	558
8	Phase II Study of Carboplatin in Children With Progressive Low-Grade Gliomas 2002 ·Journal of Clinical Oncology ·Sridharan Gururangan, (unknown), David M. Ashley, James E. Herndon, Carol S. Bruggers, Albert Moghrabi, (unknown), Melody Watral, Sandra Tourt-Uhlig, David A. Reardon, Henry S. Friedman	76
9	Phase II study of irinotecan (CPT-11) in children with high-riskmalignant brain tumors: The Duke experience 2002 ·Neuro-Oncology ·Christopher D. Turner, Sridharan Gururangan, James D. Eastwood, (unknown), Melody Watral, (unknown), Roger E. McLendon, Allan H. Friedman, Sandra Tourt-Uhlig, Langdon L. Miller, Henry S. Friedman	63
10	Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: The Duke experience 2002 ·Neuro-Oncology ·Christopher Turner, Sridharan Gururangan, J.W. Eastwood, (unknown), Melody Watral, (unknown), Roger E. McLendon, Allan H. Friedman, Sandra Tourt-Uhlig, Langdon L. Miller, Henry S. Friedman	2
11	Phase II Trial of Carmustine Plus O⁶-Benzylguanine for Patients With Nitrosourea-Resistant Recurrent or Progressive Malignant Glioma 2002 ·Journal of Clinical Oncology ·Jennifer A. Quinn, James M. Pluda, M. Eileen Dolan, Shannon M. Delaney, Richard Kaplan, Jeremy N. Rich, Allan H. Friedman, David A. Reardon, John H. Sampson, O. Michael Colvin, Michael M. Haglund, Anthony E. Pegg, Robert C. Moschel, Roger E. McLendon, James M. Provenzale, Sridharan Gururangan, Sandra Tourt-Uhlig, James E. Herndon, Darell D. Bigner, Henry S. Friedman	158
12	Phase I study of Gliadel™ wafers plus temozolomide in adults withrecurrent supratentorial high-grade gliomas 2001 ·Neuro-Oncology ·Sridharan Gururangan, Ilkcan Cokgor, Jeremy N. Rich, (unknown), Mary Lou Affronti, Jennifer A. Quinn, James E. Herndon, James M. Provenzale, Roger E. McLendon, Sandra Tourt-Uhlig, John H. Sampson, (unknown), Sara Zaknoen, Maureen Early, Alan H. Friedman, (unknown)	64

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact